The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Empagliflozin in Post AKI Stage 2-3

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Central Chest Institute of Thailand

Nonthaburi, Mueang Nonthaburi District, 11000, Thailand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

post AKI stage 2-3
CrCl > 20

Exclusion criteria

pregnancy
post kidney transplant
previous use of SGLT2 Inhibitors
history of ketoacidosis

Treatment and study plan

Empagliflozin 10 MG

Drug

SGLT2 inhibitors

Placebo

Drug

Placebo

Primary outcomes

MAKE365

Time frame: 1 year

Major adverse kidney events (number of participants with death, renal replacement therapy, New CKD, CKD progression)

Sponsors and collaborators

Lead sponsor

Chulalongkorn University

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2026
First posted: May 4, 2022
Registry last updated: Aug 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.